http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 15:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Jun+02/26591213.html si-local-file:///var/storage/secattach/20260602/26591213.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Jun+02/26591213.html Tue, 02 Jun 2026 15:35:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Jun+02/26591213.html si-local-file:///var/storage/secattach/20260602/26591213.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Jun+02/26591213.html Tue, 02 Jun 2026 15:35:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PDS+Biotechnology+Corp++++For%3A+Mar+31/26494823.html si-local-file:///var/storage/secattach/20260514/26494823.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PDS+Biotechnology+Corp++++For%3A+Mar+31/26494823.html Thu, 14 May 2026 16:08:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PDS+Biotechnology+Corp++++For%3A+Mar+31/26494823.html si-local-file:///var/storage/secattach/20260514/26494823.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PDS+Biotechnology+Corp++++For%3A+Mar+31/26494823.html Thu, 14 May 2026 16:08:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+May+13/26481535.html si-local-file:///var/storage/secattach/20260513/26481535.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+May+13/26481535.html Wed, 13 May 2026 07:05:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+May+13/26481535.html si-local-file:///var/storage/secattach/20260513/26481535.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+May+13/26481535.html Wed, 13 May 2026 07:05:00 -0400 O.07417570 PDSB http://www.streetinsider.com/Earnings/PDS+Biotechnology+%28PDSB%29+Tops+Q1+EPS+by+2c/26481513.html <p>PDS Biotechnology (NASDAQ: PDSB) reported Q1 EPS of ($0.13), $0.02 better than the analyst estimate of ($0.15).</p><p>For earnings history and earnings-related data on PDS Biotechnology (PDSB) <a href="http://www.streetinsider.com/ec_earnings.php?q=PDSB">click here</a>.</p> http://www.streetinsider.com/Earnings/PDS+Biotechnology+%28PDSB%29+Tops+Q1+EPS+by+2c/26481513.html Wed, 13 May 2026 07:03:07 -0400 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Press+Releases/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html <p align="center"><em>Investor Webcast Scheduled for 8:00 am ET</em></p> <p>PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended March 31, 2026.</p> <p>“During the first quarter, we made meaningful clinical and regulatory progress across our clinical pipeline,” said Frank Bedu-Addo, PhD, President and CEO of PDS Biotech. “We work towards http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Reports+First+Quarter+2026+Financial+Results+and+Provides+Clinical+Programs+and+Corporate+Update/26481413.html Wed, 13 May 2026 07:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Press+Releases/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html <p>PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call and webcast to report financial results for the quarter ended March 31, 2026, and will provide a clinical programs and corporate update, on Wednesday, May 13, 2026 at 8:00 am Eastern Time.</p> <p><strong>Conference Call Details</strong><br></br></p> <p style="padding-left:40px;">Date: May 13, 2026<br></br>Time: 8:00 a.m. Eastern Time<br></br>Dial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International)<br></br>Conference I.D.: 13760368<br></br>CallMeTM: <a target="_blank" http://www.streetinsider.com/Globe+Newswire/PDS+Biotech+Announces+Conference+Call+and+Webcast+for+2026+First+Quarter+Financial+Results/26439433.html Wed, 06 May 2026 08:00:00 -0400 A.50216777 O.07417570 O.54516537 PDSB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Apr+30/26415607.html si-local-file:///var/storage/secattach/20260501/26415607.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Apr+30/26415607.html Fri, 01 May 2026 12:26:00 -0400 O.07417570 PDSB http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Apr+30/26415607.html si-local-file:///var/storage/secattach/20260501/26415607.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PDS+Biotechnology+Corp++++For%3A+Apr+30/26415607.html Fri, 01 May 2026 12:26:00 -0400 O.07417570 PDSB